Camiel J F Boon

List of Publications by Year in Descending Order

149 papers	4,749 citations	42 h-index	64 g-index
160 ext. papers	6,135 ext. citations	6.3 avg, IF	5.5 L-index

#	Paper	IF	Citations
149	Estimation of current and post-treatment retinal function in chronic central serous chorioretinopathy using artificial intelligence. *Scientific Reports*, **2021**, 11, 20446	4.9	0
148	CLINICAL CHARACTERISTICS AND NATURAL HISTORY OF RHO-ASSOCIATED RETINITIS PIGMENTOSA: A Long-Term Follow-Up Study. *Retina*, **2021**, 41, 213-223	3.6	7
147	Photodynamic therapy as a treatment option for peripapillary pachychoroid syndrome: a pilot study. *Eye*, **2021**,	4.4	2
146	Venous overload choroidopathy: A hypothetical framework for central serous chorioretinopathy and allied disorders. *Progress in Retinal and Eye Research*, **2021**, 100973	20.5	15
145	Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data. *Acta Ophthalmologica*, **2021**,	3.7	1
144	The Role of Small Molecules and Their Effect on the Molecular Mechanisms of Early Retinal Organoid Development. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	3
143	Half-Dose Photodynamic Therapy Versus Eplerenone in Chronic Central Serous Chorioretinopathy (SPECTRA): A Randomized Controlled Trial. *American Journal of Ophthalmology*, **2021**, 233, 101-110	4.9	1
142	CRB1-Associated Retinal Dystrophies: A Prospective Natural History Study in Anticipation of Future Clinical Trials. *American Journal of Ophthalmology*, **2021**, 234, 37-48	4.9	2
141	Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2021**, 259, 905-910	3.8	2
140	The spectrum of polypoidal choroidal vasculopathy in Caucasians: clinical characteristics and proposal of a classification. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2021**, 259, 351-361	3.8	1
139	Central serous chorioretinopathy in active endogenous Cushing's syndrome. *Scientific Reports*, **2021**, 11, 2748	4.9	3
138	Defining inclusion criteria and endpoints for clinical trials: a prospective cross-sectional study in CRB1-associated retinal dystrophies. *Acta Ophthalmologica*, **2021**, 99, e402-e414	3.7	2
137	Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser. *Acta Ophthalmologica*, **2021**, 99, 805-811	3.7	1
136	-associated retinal dystrophies in a Belgian cohort: genetic characteristics and long-term clinical follow-up. *British Journal of Ophthalmology*, **2021**,	5.5	6
135	The Lrat Rat: CRISPR/Cas9 Construction and Phenotyping of a New Animal Model for Retinitis Pigmentosa. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
134	Phenotypic Consequences of the GJD2 Risk Genotype in Myopia Development **2021**, 62, 16		1
133	The Phenotypic Spectrum of Patients with PHARC Syndrome Due to Variants in : An Ophthalmic Perspective. *Genes*, **2021**, 12,	4.2	2

132	PRPH2 mutation update: In silico assessment of 245 reported and 7 novel variants in patients with retinal disease. *Human Mutation*, **2021**, 42, 1521-1547	4.7	0
131	Serous business: Delineating the broad spectrum of diseases with subretinal fluid in the macula. *Progress in Retinal and Eye Research*, **2021**, 84, 100955	20.5	9
130	The Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathy. *Journal of Clinical Endocrinology and Metabolism*, **2021**,	5.6	1
129	Response to Letter to the editor from Behar-Cohen, et al: The Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathy.. *Journal of Clinical Endocrinology and Metabolism*, **2021**,	5.6	1
128	Resolving the dark matter of ABCA4 for 1054 Stargardt disease probands through integrated genomics and transcriptomics. *Genetics in Medicine*, **2020**, 22, 1235-1246	8.1	44
127	Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities. *Progress in Retinal and Eye Research*, **2020**, 79, 100865	20.5	45
126	Retinal Dystrophies and the Road to Treatment: Clinical Requirements and Considerations. *Asia-Pacific Journal of Ophthalmology*, **2020**, 9, 159-179	3.5	9
125	Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2020**, 258, 1191-1197	3.8	2
124	Stress and vision-related quality of life in acute and chronic central serous chorioretinopathy. *BMC Ophthalmology*, **2020**, 20, 90	2.3	4
123	-Associated Dystrophies: Clinical, Genetic, and Histopathological Features. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	13
122	GENETIC RISK FACTORS IN SEVERE, NONSEVERE AND ACUTE PHENOTYPES OF CENTRAL SEROUS CHORIORETINOPATHY. *Retina*, **2020**, 40, 1734-1741	3.6	7
121	Reply to Comment on: Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3. *American Journal of Ophthalmology*, **2020**, 212, 187-188	4.9	6
120	Choroidal Anatomic Alterations After Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: A Multicenter Study. *American Journal of Ophthalmology*, **2020**, 217, 104-113	4.9	13
119	Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach. *Ophthalmology and Therapy*, **2020**, 9, 329-342	5	8
118	Hair cortisol concentrations in chronic central serous chorioretinopathy. *Acta Ophthalmologica*, **2020**, 98, 390-395	3.7	2
117	CLINICAL CHARACTERISTICS AND OUTCOME OF POSTERIOR CYSTOID MACULAR DEGENERATION IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. *Retina*, **2020**, 40, 1742-1750	3.6	7
116	Clinical Phenotype and Course of PDE6A-Associated Retinitis Pigmentosa Disease, Characterized in Preparation for a Gene Supplementation Trial. *JAMA Ophthalmology*, **2020**, 138, 1241-1250	3.9	7
115	MAINTENANCE OF GOOD VISUAL ACUITY IN BEST DISEASE ASSOCIATED WITH CHRONIC BILATERAL SEROUS MACULAR DETACHMENT. *Retinal Cases and Brief Reports*, **2020**, 14, 1-5	1.1	4

114	Long-Term Follow-Up of Retinal Degenerations Associated With Mutations and Their Comparability to Phenotypes Associated With Mutations. *Translational Vision Science and Technology*, **2019**, 8, 24	3.3	6
113	Reply. *Ophthalmology*, **2019**, 126, e30-e31	7.3	
112	GENETIC RISK FACTORS IN ACUTE CENTRAL SEROUS CHORIORETINOPATHY. *Retina*, **2019**, 39, 2303-2310	3.6	10
111	Patient characteristics of untreated chronic central serous chorioretinopathy patients with focal versus diffuse leakage. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2019**, 257, 1419-1425	3.8	12
110	Exome sequencing in patients with chronic central serous chorioretinopathy. *Scientific Reports*, **2019**, 9, 6598	4.9	7
109	The Ocular Phenotype in Primary Hyperoxaluria Type 1. *American Journal of Ophthalmology*, **2019**, 206, 184-191	4.9	13
108	Macular Dystrophy and Cone-Rod Dystrophy Caused by Mutations in the RP1 Gene: Extending the RP1 Disease Spectrum **2019**, 60, 1192-1203		17
107	Human iPSC-Derived Retinas Recapitulate the Fetal CRB1 CRB2 Complex Formation and Demonstrate that Photoreceptors and Müller Glia Are Targets of AAV5. *Stem Cell Reports*, **2019**, 12, 906-919	8	42
106	Photodynamic Therapy in Central Serous Chorioretinopathy **2019**, 283-292		1
105	Focal and Diffuse Chronic Central Serous Chorioretinopathy Treated With Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser: PLACE Trial Report No. 3. *American Journal of Ophthalmology*, **2019**, 205, 1-10	4.9	24
104	Exome sequencing in families with chronic central serous chorioretinopathy. *Molecular Genetics & Genomic Medicine*, **2019**, 7, e00576	2.3	9
103	Discrepancy in current central serous chorioretinopathy classification. *British Journal of Ophthalmology*, **2019**, 103, 737-742	5.5	28
102	Elevated Steroid Hormone Levels in Active Chronic Central Serous Chorioretinopathy **2019**, 60, 3407-3413		6
101	Foveal Sparing in Central Retinal Dystrophies **2019**, 60, 3456-3467		13
100	Central serous chorioretinopathy: Towards an evidence-based treatment guideline. *Progress in Retinal and Eye Research*, **2019**, 73, 100770	20.5	122
99	An international collaborative evaluation of central serous chorioretinopathy: different therapeutic approaches and review of literature. The European Vitreoretinal Society central serous chorioretinopathy study. *Acta Ophthalmologica*, **2019**, 98, e549	3.7	5
98	Genome-wide association analyses identify two susceptibility loci for pachychoroid disease central serous chorioretinopathy. *Communications Biology*, **2019**, 2, 468	6.7	19
97	On the origin of proteins in human drusen: The meet, greet and stick hypothesis. *Progress in Retinal and Eye Research*, **2019**, 70, 55-84	20.5	44

96	Reply. *Ophthalmology*, **2019**, 126, e11	7.3	
95	Maladaptive personality traits, psychological morbidity and coping strategies in chronic central serous chorioretinopathy. *Acta Ophthalmologica*, **2019**, 97, e572-e579	3.7	10
94	Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-RISK and European Eye Epidemiology Consortia. *Ophthalmology*, **2019**, 126, 393-406	7.3	49
93	FAMILIAL CENTRAL SEROUS CHORIORETINOPATHY. *Retina*, **2019**, 39, 398-407	3.6	12
92	CLINICAL AND GENETIC CHARACTERISTICS OF MALE PATIENTS WITH RPGR-ASSOCIATED RETINAL DYSTROPHIES: A Long-Term Follow-up Study. *Retina*, **2019**, 39, 1186-1199	3.6	32
91	Pimasertib-associated ophthalmological adverse events. *Acta Ophthalmologica*, **2018**, 96, 712-718	3.7	5
90	Systemic and Ocular Determinants of Peripapillary Retinal Nerve Fiber Layer Thickness Measurements in the European Eye Epidemiology (E3) Population. *Ophthalmology*, **2018**, 125, 1526-1536	7.3	41
89	Non-syndromic retinitis pigmentosa. *Progress in Retinal and Eye Research*, **2018**, 66, 157-186	20.5	294
88	The Decreasing Prevalence of Nonrefractive Visual Impairment in Older Europeans: A Meta-analysis of Published and Unpublished Data. *Ophthalmology*, **2018**, 125, 1149-1159	7.3	9
87	Antiretinal antibodies in central serous chorioretinopathy: prevalence and clinical implications. *Acta Ophthalmologica*, **2018**, 96, 56-62	3.7	4
86	LONG-TERM FOLLOW-UP OF PATIENTS WITH CHOROIDEREMIA WITH SCLERAL PITS AND TUNNELS AS A NOVEL OBSERVATION. *Retina*, **2018**, 38, 1713-1724	3.6	8
85	Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study. *JAMA Ophthalmology*, **2018**, 136, 1128-1136	3.9	27
84	Cushing's Syndrome and Hypothalamic-Pituitary-Adrenal Axis Hyperactivity in Chronic Central Serous Chorioretinopathy. *Frontiers in Endocrinology*, **2018**, 9, 39	5.7	13
83	Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2018**, 256, 1395-1402	3.8	17
82	Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy. *PLoS ONE*, **2018**, 13, e0202549	3.7	20
81	The Spectrum of Structural and Functional Abnormalities in Female Carriers of Pathogenic Variants in the RPGR Gene **2018**, 59, 4123-4133		27
80	Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. *Clinical Ophthalmology*, **2018**, 12, 1061-1070	2.5	25
79	Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial. *Ophthalmology*, **2018**, 125, 1547-1555	7.3	111

78	Management of central serous chorioretinopathy: Expert panel discussion. *Indian Journal of Ophthalmology*, **2018**, 66, 1700-1703	1.6	3
77	AAV Serotype Testing on Cultured Human Donor Retinal Explants. *Methods in Molecular Biology*, **2018**, 1715, 275-288	1.4	7
76	Recording and Analysis of Goldmann Kinetic Visual Fields. *Methods in Molecular Biology*, **2018**, 1715, 327-338	1.4	5
75	Measuring Central Retinal Sensitivity Using Microperimetry. *Methods in Molecular Biology*, **2018**, 1715, 339-349	1.4	4
74	SHORT-TERM FINDINGS ON OPTICAL COHERENCE TOMOGRAPHY AND MICROPERIMETRY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY PATIENTS TREATED WITH HALF-DOSE PHOTODYNAMIC THERAPY. *Retinal Cases and Brief Reports*, **2018**, 12, 266-271	1.1	10
73	The Effect of Corticosteroids on Human Choroidal Endothelial Cells: A Model to Study Central Serous Chorioretinopathy **2018**, 59, 5682-5692		10
72	Clinical spectrum of severe chronic central serous chorioretinopathy and outcome of photodynamic therapy. *Clinical Ophthalmology*, **2018**, 12, 2167-2176	2.5	13
71	The Common ABCA4 Variant p.Asn1868Ile Shows Nonpenetrance and Variable Expression of Stargardt Disease When Present in trans With Severe Variants **2018**, 59, 3220-3231		45
70	Diagnostic exome sequencing in 266 Dutch patients with visual impairment. *European Journal of Human Genetics*, **2017**, 25, 591-599	5.3	68
69	Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy. *JAMA Ophthalmology*, **2017**, 135, 446-451	3.9	49
68	Genotypic and Phenotypic Characteristics of CRB1-Associated Retinal Dystrophies: A Long-Term Follow-up Study. *Ophthalmology*, **2017**, 124, 884-895	7.3	47
67	Preferred practice pattern in central serous chorioretinopathy. *British Journal of Ophthalmology*, **2017**, 101, 587-590	5.5	29
66	Spectrum of retinal abnormalities in renal transplant patients using chronic low-dose steroids. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2017**, 255, 2443-2449	3.8	3
65	Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2017**, 255, 2029-2035	3.8	8
64	Dystrophies **2017**, 63-72		
63	Outcome of Full-Thickness Macular Hole Surgery in Choroideremia. *Genes*, **2017**, 8,	4.2	4
62	Systemic complement activation in central serous chorioretinopathy. *PLoS ONE*, **2017**, 12, e0180312	3.7	7
61	Neovascular age-related macular degeneration without drusen in the fellow eye: clinical spectrum and therapeutic outcome. *Clinical Ophthalmology*, **2017**, 11, 63-70	2.5	3

60	Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. *Clinical Ophthalmology*, **2017**, 11, 39-46	2.5	66
59	Central serous chorioretinopathy in primary hyperaldosteronism. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2016**, 254, 2033-2042	3.8	19
58	Association of Axial Length With Risk of Uncorrectable Visual Impairment for Europeans With Myopia. *JAMA Ophthalmology*, **2016**, 134, 1355-1363	3.9	125
57	Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients. *Medicine (United States)*, **2016**, 95, e3457	1.8	23
56	Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. *Acta Ophthalmologica*, **2016**, 94, 187-97	3.7	21
55	Efficacy of photodynamic therapy in steroid-associated chronic central serous chorioretinopathy: a case-control study. *Acta Ophthalmologica*, **2016**, 94, 565-72	3.7	11
54	Rare Genetic Variants Associated With Development of Age-Related Macular Degeneration. *JAMA Ophthalmology*, **2016**, 134, 287-93	3.9	35
53	Mutations in CTNNA1 cause butterfly-shaped pigment dystrophy and perturbed retinal pigment epithelium integrity. *Nature Genetics*, **2016**, 48, 144-51	36.3	35
52	Analysis of Risk Alleles and Complement Activation Levels in Familial and Non-Familial Age-Related Macular Degeneration. *PLoS ONE*, **2016**, 11, e0144367	3.7	9
51	Whole Exome Sequencing in Patients with the Cuticular Drusen Subtype of Age-Related Macular Degeneration. *PLoS ONE*, **2016**, 11, e0152047	3.7	24
50	Mitochondrial Retinal Dystrophy Associated with the (m.3243A>G) Mutation **2016**, 63-69		
49	Miscellaneous Rare Macular Dystrophies **2016**, 83-99		
48	The Pattern Dystrophies **2016**, 11-23		
47	Chronic central serous chorioretinopathy as a presenting symptom of Cushing syndrome. *European Journal of Ophthalmology*, **2016**, 26, 442-8	1.9	21
46	BESTROPHINOPATHY: A Spectrum of Ocular Abnormalities Caused by the c.614T>C Mutation in the BEST1 Gene. *Retina*, **2016**, 36, 1586-95	3.6	17
45	Adult-onset foveomacular vitelliform dystrophy: A fresh perspective. *Progress in Retinal and Eye Research*, **2015**, 47, 64-85	20.5	62
44	Clinical Utility Gene Card for: autosomal recessive cone-rod dystrophy. *European Journal of Human Genetics*, **2015**, 23,	5.3	10
43	Early-onset stargardt disease: phenotypic and genotypic characteristics. *Ophthalmology*, **2015**, 122, 335-44	7.3	97

42	Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. *Ophthalmology*, **2015**, 122, 562-70	7.3	82
41	Reply: To PMID 25267528. *Ophthalmology*, **2015**, 122, e60	7.3	2
40	Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial. *Trials*, **2015**, 16, 419	2.8	36
39	Correspondence. *Retina*, **2015**, 35, e52-4	3.6	
38	Correspondence. *Retina*, **2015**, 35, e57-8	3.6	
37	Genomic Copy Number Variations of the Complement Component C4B Gene Are Associated With Chronic Central Serous Chorioretinopathy **2015**, 56, 5608-13		30
36	OCT Angiography Compared to Fluorescein and Indocyanine Green Angiography in Chronic Central Serous Chorioretinopathy **2015**, 56, 5229-37		104
35	Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. *Ophthalmology*, **2015**, 122, 1907-16	7.3	46
34	Subthreshold Micropulse Laser (577 nm) Treatment in Chronic Central Serous Chorioretinopathy. *Ophthalmologica*, **2015**, 234, 189-94	3.7	37
33	Dominant cystoid macular dystrophy. *Ophthalmology*, **2015**, 122, 180-91	7.3	14
32	The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. *Acta Ophthalmologica*, **2014**, 92, e488-90	3.7	32
31	Macular dystrophies mimicking age-related macular degeneration. *Progress in Retinal and Eye Research*, **2014**, 39, 23-57	20.5	51
30	Foveal sparing in Stargardt disease **2014**, 55, 7467-78		45
29	Clinical characteristics of familial and sporadic age-related macular degeneration: differences and similarities **2014**, 55, 7085-92		6
28	Pars plana vitrectomy for disturbing primary vitreous floaters: clinical outcome and patient satisfaction. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2013**, 251, 1373-82	3.8	57
27	Cuticular drusen: stars in the sky. *Progress in Retinal and Eye Research*, **2013**, 37, 90-113	20.5	46
26	Mitochondrial retinal dystrophy associated with the m.3243A>G mutation. *Ophthalmology*, **2013**, 120, 2684-2696	7.3	51
25	Autosomal recessive bestrophinopathy: differential diagnosis and treatment options. *Ophthalmology*, **2013**, 120, 809-20	7.3	90

24	A functional variant in the CFI gene confers a high risk of age-related macular degeneration. *Nature Genetics*, **2013**, 45, 813-7	36.3	134
23	A rare nonsynonymous sequence variant in C3 is associated with high risk of age-related macular degeneration. *Nature Genetics*, **2013**, 45, 1371-4	36.3	104
22	Increased fundus autofluorescence related to outer retinal disruption. *JAMA Ophthalmology*, **2013**, 131, 1645-9	3.9	64
21	Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration. *Ophthalmology*, **2012**, 119, 339-46	7.3	106
20	Clinical course, genetic etiology, and visual outcome in cone and cone-rod dystrophy. *Ophthalmology*, **2012**, 119, 819-26	7.3	99
19	Clinical and genetic characteristics of late-onset Stargardt's disease. *Ophthalmology*, **2012**, 119, 1199-210	7.3	120
18	Short-term changes of Basal laminar drusen on spectral-domain optical coherence tomography. *American Journal of Ophthalmology*, **2012**, 154, 560-7	4.9	14
17	Genetic, behavioral, and sociodemographic risk factors for second eye progression in age-related macular degeneration **2012**, 53, 5846-52		17
16	Clinical evaluation of 3 families with basal laminar drusen caused by novel mutations in the complement factor H gene. *JAMA Ophthalmology*, **2012**, 130, 1038-47		29
15	Central areolar choroidal dystrophy (CACD) and age-related macular degeneration (AMD): differentiating characteristics in multimodal imaging **2011**, 52, 8908-18		42
14	Course of visual decline in relation to the Best1 genotype in vitelliform macular dystrophy. *Ophthalmology*, **2010**, 117, 1415-22	7.3	27
13	The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. *Progress in Retinal and Eye Research*, **2009**, 28, 187-205	20.5	241
12	Near-infrared reflectance imaging of neovascular age-related macular degeneration. *Graefe's Archive for Clinical and Experimental Ophthalmology*, **2009**, 247, 1625-33	3.8	25
11	Central areolar choroidal dystrophy. *Ophthalmology*, **2009**, 116, 771-82, 782.e1	7.3	72
10	The spectrum of phenotypes caused by variants in the CFH gene. *Molecular Immunology*, **2009**, 46, 1573-94	4.3	70
9	Extensive macular atrophy with pseudodrusen-like appearance: a new clinical entity. *American Journal of Ophthalmology*, **2009**, 148, 173-4; author reply 174-5	4.9	4
8	Clinical and molecular genetic analysis of best vitelliform macular dystrophy. *Retina*, **2009**, 29, 835-47	3.6	57
7	Fundus autofluorescence imaging of retinal dystrophies. *Vision Research*, **2008**, 48, 2569-77	2.1	60

6	The spectrum of retinal dystrophies caused by mutations in the peripherin/RDS gene. *Progress in Retinal and Eye Research*, **2008**, 27, 213-35	20.5	153
5	Reflux after intravitreal injection of bevacizumab. *Ophthalmology*, **2008**, 115, 1270; author reply 1271	7.3	24
4	Basal laminar drusen caused by compound heterozygous variants in the CFH gene. *American Journal of Human Genetics*, **2008**, 82, 516-23	11	82
3	Mutations in the peripherin/RDS gene are an important cause of multifocal pattern dystrophy simulating STGD1/fundus flavimaculatus. *British Journal of Ophthalmology*, **2007**, 91, 1504-11	5.5	83
2	Clinical and genetic heterogeneity in multifocal vitelliform dystrophy. *JAMA Ophthalmology*, **2007**, 125, 1100-6		73
1	Erosive vitreoretinopathy and wagner disease are caused by intronic mutations in CSPG2/Versican that result in an imbalance of splice variants. *Investigative Ophthalmology and Visual Science*, **2006**, 47, 3565-72		65